NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal ...

Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal ...

Morgan Stanley has downgraded Intellia Therapeutics (NASDAQ:NTLA) to equal weight from overweight citing "a more measured launch" of its transthyretin amyloidosis (ATTR) candidate nexiguran ziclumeran ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization. Read more about EDIT and NTLA stocks here.

NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target dropped by equities research analysts at BMO Capital Markets from $70.00 to $50.00 in a research report issued to clients and ...

NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Morgan Stanley has downgraded Intellia Therapeutics (NASDAQ:NTLA) to equal weight from overweight citing "a more measured launch" of its transthyretin amyloidosis (ATTR) candidate nexiguran ...